Alzamend Neuro, Inc. (ALZN)
NASDAQ: ALZN · Real-Time Price · USD
1.240
-0.060 (-4.62%)
At close: Nov 13, 2026, 4:00 PM EST
1.240
0.00 (0.00%)
After-hours: Nov 13, 2026, 4:15 PM EST
Alzamend Neuro Employees
As of July 31, 2026, Alzamend Neuro had 6 total employees, including 4 full-time and 2 part-time employees. The number of employees did not change since the number was last reported on April 30, 2026. That makes Alzamend Neuro the 41,299th largest employer in the world and 6,360th in the United States.
Employees
6
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,516,117
Market Cap
5.98M
Employees Chart
| Date | Employees | Change | Growth | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Jul 31, 2026 | 6 | 0 | - | 4 | 2 |
| Apr 30, 2026 | 6 | -1 | -14.29% | 4 | 2 |
| Apr 30, 2025 | 7 | 0 | - | 4 | 3 |
| Apr 30, 2024 | 7 | 0 | - | 4 | 3 |
| Apr 30, 2023 | 7 | -1 | -12.50% | 4 | 3 |
| Apr 30, 2022 | 8 | 2 | 33.33% | 4 | 4 |
| Apr 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Evogene | 52 |
| Theriva Biologics | 16 |
| Lantern Pharma | 16 |
| FibroBiologics | 15 |
| Soligenix | 14 |
| Processa Pharmaceuticals | 12 |
| Ensysce Biosciences | 10 |
| Enveric Biosciences | 6 |
ALZN News
- 1 month ago - Alzamend Neuro regains Nasdaq compliance - TheFly
- 2 months ago - Alzamend Neuro Quarterly report: Q1 2027 - Filings
- 2 months ago - Alzamend Neuro Proxy statement: Proxy filing - Filings
- 2 months ago - Alzamend Neuro registers to sell 98.39M shares of common stock for holders - TheFly
- 2 months ago - Alzamend Neuro Registration statement: Registration filing - Filings
- 2 months ago - Alzamend Neuro's Phase 1/2A Lithium Neuroimaging Data Accepted for Poster Presentation at Neuroscience 2026 in Washington, DC - PRNewsWire
- 2 months ago - Alzamend Neuro's Phase 1/2A Lithium Imaging Data Accepted for Oral Presentation at ISMRM Workshop on X-Nuclei MR in Barcelona, Spain - PRNewsWire
- 3 months ago - Alzamend Neuro Announces Initial Closing of Securities Purchase Agreement with Ault Lending - PRNewsWire